S
Suzhou Xuanjing Biotechnology
Research and development of innovative small nucleic acid drugs
About Suzhou Xuanjing Biotechnology
Suzhou Xuanjing Biotechnology, operating as Rigerna, is a clinical-stage biopharmaceutical firm established in 2022, specializing in the development of small interfering RNA (siRNA) therapeutics. The company was founded by Dr. Yuanyu Huang, a distinguished scientist with more than 16 years of academic and industrial experience in the oligonucleotide field. His expertise is underscored by his ranking in the top 0.26% of the “Most Influential Scientists Globally” list, which provides a strong scientific foundation for the company's pursuits. The name 'Rigerna' is a blend of 'Rigel', one of the brightest stars, and 'RNA', reflecting the company's ambition to make significant achievements in the RNAi field.
Rigerna's strategic focus is on addressing unmet medical needs in kidney diseases. The company's business model centers on creating a pipeline of proprietary drug assets by leveraging its in-house technology platforms. These assets are then advanced through clinical development, with the potential for future licensing or commercialization partnerships. The company has secured over $30 million in initial seed and angel financing to support its research and development activities. Its operations are based in Suzhou and Beijing, China.
The core of Rigerna's operations lies in its three proprietary technology platforms: a nucleic acid sequence design and screening platform, a chemical modification platform, and an in-vivo delivery platform. This integrated approach underpins the development of its product pipeline, led by RG002, an siRNA therapeutic candidate for treating IgA nephropathy (IgAN). RG002, which is currently in Phase 1 clinical trials, has shown promise by reducing a key biomarker for IgAN by approximately 60% in non-human primate models. A key differentiator for the company is its novel kidney-targeting delivery platform, which has successfully completed proof-of-concept experiments in non-human primates, demonstrating efficient and targeted delivery of siRNA to the kidneys.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Apr 2026 | $28M | $114M | Bayland Capital | ↗ |
| SEEDOther financing | Apr 2025 | $14M | $55M | Guolian Group | ↗ |
Growth signals
Latest recorded traffic for Suzhou Xuanjing Biotechnology is 840 monthly website visits, up 1580% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Xuanjing Biotechnology in the Suzhou Shi ecosystem
The Suzhou Xuanjing Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
- SIShanghai Science and Technology Investment
- YFYuanxi Haihe Fund
GSR United Capital
Trinity Innovation Fund- GGGuolian Group
Series A1 investor entered at this stage
Bayland Capital
Other known investors1 additional known investor
Beijing Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Xuanjing Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Xuanjing Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









